Acute ST Segment Elevation Myocardial Infarction Clinical Trial
Official title:
International, Double Blind, Randomized, Placebo-controlled Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
The goal of the study was to evaluate the effect of single administration of RPH-104 at 80 mg and 160 mg on parameters of systemic inflammation and outcomes of the disease in subjects with ST-segment elevation myocardial infarction (STEMI)
After signing the informed consent form, the investigator assessed the subject's eligibility for the study. The following procedures were performed during the screening: collection of medical history, recording previous and concomitant therapy, demographic data, recording 12-lead ECG findings on which STEMI diagnosis was based, recording date and time of STEMI symptom development, recording date, time and results of coronary angiography (CAG) at admission to the study site, measurement of blood neutrophil count, vital signs, physical examination including measurement of body weight (if hospital bed is available), blood sampling for hematology, biochemistry, determination of concentration of hsCRP and brain natriuretic peptide (BNP; N-terminal (NT)-pro hormone brain natriuretic peptide (NT-pro-BNP)), for females with retained reproductive potential - pregnancy test (test strips). The subjects meeting selection criteria were randomized to one of the three groups (in 1:1:1 ratio) for single subcutaneous administration of RPH-104 80 mg, RPH-104 160 mg or placebo. Screening, randomization and administration of the study products were made on the same (first) study day. Further 4-week (28-day) clinical follow-up and additional 6- and 12-month clinical follow-up period were performed. The end of clinical part of the study was the date of the last visit of the last subject within additional 12-month clinical follow-up. The maximum number of screened patients was planned to be 146 subjects, 102 subjects were randomized, 34 subjects per group. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02914795 -
Platelet Function in Resuscitated Patients
|
||
| Recruiting |
NCT00697021 -
Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance
|
Phase 3 | |
| Completed |
NCT05949515 -
Retrospective Evaluation of SuperSaturated Oxygen (SSO2) Therapy Clinical Utility
|
||
| Completed |
NCT02828683 -
Safety and Efficacy of TCD-10023 (Ultimaster) Drug-eluting Stent in STEMI Patients - MASTER Study
|
N/A | |
| Completed |
NCT01986803 -
ABSORB STEMI: the TROFI II Study
|
N/A | |
| Active, not recruiting |
NCT01878344 -
Effects of N-acetyl Cysteine During Primary Percutaneous Coronary Intervention
|
Phase 3 | |
| Withdrawn |
NCT02048085 -
Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis
|
Phase 4 | |
| Active, not recruiting |
NCT02943954 -
FLOW Evaluation to Guide Revascularization in Multi-vessel ST-elevation Myocardial Infarction
|
N/A | |
| Completed |
NCT02298088 -
Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis
|
Phase 3 | |
| Active, not recruiting |
NCT02067091 -
Performance of Bioresorbable Scaffold in Primary Percutaneous Intervention of ST Elevation Myocardial Infarct
|
Phase 3 | |
| Completed |
NCT01787110 -
An Efficacy and Outcome Study of Supplemental Oxygen Treatment in Patients With Suspected Myocardial Infarction
|
Phase 3 | |
| Recruiting |
NCT03137212 -
Safety and Efficacy of Percutaneous Coronary Intervention Combined With Thrombolysis at Different Time
|
N/A | |
| Not yet recruiting |
NCT05802667 -
A Cohort Study of Correlation Between Mast Cells and Prognosis in Patients With Acute Myocardial Infarction
|
||
| Completed |
NCT04730778 -
Predictive Value of CHA2DS2VASC Score for Contrast-induced Nephropathy After Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction Patients
|